---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-117587"
form_type: "8-K"
ticker: "ABT"
cik: "0000001800"
company_name: "ABBOTT LABORATORIES"
filed_at: "2026-10-21T13:19:51+00:00"
generated_at: "2026-10-21T13:21:06.086164+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Abbott to spin off $8.5B Nutrition business via tax-free distribution by end of 2027

## Summary
- Nutrition spin-off will hold Similac, PediaSure, Pedialyte, Glucerna and Ensure, with ~$8.5B annual sales, ~16,000 employees and 14 manufacturing sites.
- Remaining Abbott will have ~$42B in sales and ~106,000 employees, focused on medical devices, biowearables, diagnostics and established medicines.
- Separation structured as a tax-free distribution to Abbott shareholders; combined Abbott and Nutrition dividends expected to equal Abbott's current payout.
- Daniel Salvadori, EVP and group president of Established Pharmaceuticals and Nutritional Products, will become CEO of the new Nutrition company.
- Abbott reaffirmed 2026 guidance and said 2027 guidance, due in January, is unaffected; one-time transaction charges to be quantified later.

## SEC filing metadata
- accession: 0001104659-26-117587
- form_type: 8-K
- ticker: ABT
- cik: 0000001800
- company_name: ABBOTT LABORATORIES
- filed_at: 2026-10-21T13:19:51+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800/000110465926117587/0001104659-26-117587-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800/000110465926117587/tm2627971d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-117587
- JSON: https://secwatch.observer/filing/0001104659-26-117587.json
- Plain text: https://secwatch.observer/filing/0001104659-26-117587.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.